49.89
-0.21 (-0.42%)
| Previous Close | 50.10 |
| Volume | 1,642,136 |
| Price / Earnings (Forward) | 15.45 |
| Price / Sales | 4.91 |
| Price / Book | 2.96 |
| 52 Weeks Range | |
| TTM Dividend Yield | 0.64% |
| Profit Margin | 4.68% |
| Operating Margin (TTM) | 25.89% |
| Diluted EPS (TTM) | 0.430 |
| Quarterly Revenue Growth (YOY) | 5.40% |
| Quarterly Earnings Growth (YOY) | 12.50% |
| Total Debt/Equity (MRQ) | 41.36% |
| Current Ratio (MRQ) | 3.37 |
| Operating Cash Flow (TTM) | 680.21 M |
| Levered Free Cash Flow (TTM) | 622.84 M |
| Return on Assets (TTM) | 5.75% |
| Return on Equity (TTM) | 2.67% |
AIStockmoo Score
| Value 30% | 0.5 |
| Around its usual valuation. Counted for less, as its earnings have been uneven. info | |
| Earns below its cost of capital. info | |
| Low debt. Weak profitability. Ample short-term liquidity. Positive cash flow. info | |
| From our AI Insight report's view of expected return against risk. info | NA |
| Relative Valuation info | NA |
| Implied Growth info | NA |
| Holdings' Value info | NA |
| Risk Premium info | NA |
| Market Valuation info | NA |
| Timing 30% | 2.2 |
| No clear trend over the past year. Trading near its 52-week high. info | |
| In an uptrend: the price is above its moving averages, and they are rising. It is close to them. Volume is heavier on up days. info | |
| From our AI technical analysis of the chart. info | NA |
| Candle Patterns info | NA |
| Sentiment 20% | 0.0 |
| No recent price targets, so based on how targets have been revised. info | |
| Holdings' Sentiment info | NA |
| News Mood info | NA |
| Smart Money 20% | 4.8 |
| Institutions net +6.34% of shares in their latest 13F filings: 218 holders increased, 153 decreased (quarter to 30 Sep 2026). info | |
| Insider Activity info | NA |
| Market and sector conditions are favourable. | |
| Market environment cautious. info | |
| Sector outperforming the market. | |
| The pillars agree, so the score is strengthened. | |
| Not in score | |
| Earnings per share have gone up and down. Earnings have been uneven. info | |
| Above its medium-term trend line. info | |
| Price is high against its 52-week average. Down over 5 years. info | |
| Trend up on all three terms. Short-term momentum fading. info | |
| Price is near resistance. Levels trending up. info | |
| Final Score | 2.27 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bullish |
| Diagnostics & Research (Global) | Mixed | Bullish | |
| Stock | Qiagen N.V. | Mixed | Bullish |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B | Score |
|---|---|---|---|---|---|
| QGEN | - | 0.64% | - | 2.96 | 2.3 |
| RVTY | 17 B | 0.18% | 67.67 | 2.34 | 0.9 |
| CRL | 16 B | - | 356.45 | 4.94 | 0.7 |
| TMO | 248 B | 0.27% | 35.31 | 4.69 | 0.7 |
| DHR | 155 B | 0.67% | 36.48 | 3.00 | 0.4 |
| WAT | 87 B | - | 184.29 | 5.99 | 1.2 |
Select this tab to load the latest available analysis.
|
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%). |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Core |
| % Held by Insiders | 1.61% |
| % Held by Institutions | 86.26% |
No data within this time range.
No data within this time range.
Institutions
Institutional ownership: 76.28%
| Positions | Holders | Shares |
|---|---|---|
| Increased | 218 | 31,874,519 |
| Decreased | 153 | 18,912,886 |
| New | 67 | 5,570,055 |
| Sold out | 52 | 5,474,496 |
SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.
| Date | Type | Details |
|---|---|---|
| 13 Nov 2026 | Yahoo Finance |
Interpreting Qiagen (QGEN) International Revenue Trends
Review Qiagen's (QGEN) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock. |
| 11 Nov 2026 | Yahoo Finance |
Qiagen (QGEN) Shareholders Approve Jonathan M Pratt As CEO And Managing Director
Qiagen (NYSE:QGEN) received shareholder approval at an Extraordinary General Meeting for Jonathan M. Pratt to become CEO and Managing Director. Jonathan M. Pratt is set to succeed Thierry Bernard in the top leadership role following the Extraordinary General Meeting vote. The board decision… |
| 06 Nov 2026 | Yahoo Finance |
Qiagen (QGEN) Stock May Be Fully Priced As Sequencing Project Expands
Qiagen has delivered a 35.3% gain over the past three years, and recent headlines around genomics partnerships and sequencing markets keep the story in focus. The question now is whether that share price trajectory lines up with what the company’s cash flows can reasonably support. With a 35.3%… |
| 06 Nov 2026 | Yahoo Finance |
QIAGEN Shareholders Overwhelmingly Approve Jonathan M. Pratt as Managing Director
VENLO, Netherlands, November 06, 2026--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that shareholders overwhelmingly approved the appointment of Jonathan M. Pratt as a Managing Director and member of the QIAGEN Managing Board at an Extraordinary General Meeting of… |
Technical Setup Medium
AI Technical Analysis
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |